Получение и изучение фармакологической активности спарфлоксацина, включенного в наночастицы на основе сополимера молочной и гликолевой кислот
Диссертация
Особо перспективным путем при лечении туберкулеза является использование направленной системы транспорта лекарственных веществ на основе биодеградирующих, биосовместимых, низкотоксичных полимеров (например, сополимер молочной и гликолевой кислот) в инфицированные клетки, например в макрофаги. При циркуляции таких носителей, содержащееся в них биологически активное вещество (БАВ) защищено… Читать ещё >
Список литературы
- Аляутдин Р.Н., Джинждихашвили И.А., Курахмаева К. Б., Балабаньян
- B.Ю., Петров В. Е., Воронина Т. А. Направленный транспорт лекарственных веществ в мозг с помощью нанотранспортных систем. // Молекулярная медицина. — 2008. № 3. — С. 21−25.
- Басел А.А., Петров В. Е., Балабаньян В. Ю., Гельперина С.Э., Трофимов
- C.С, Воронина Т. А., Аляутдин Р. Н. Транспорт прозерина в головной мозг при помощи поли (бутил)цианоакрилатных наночастиц, покрытых полисорбатом-80. // Российский медю журнал. 2006. — № 4. — С. 28−38.
- Государственная фармакопея СССР XI: Выпуски 1,2: репринтное издание-М.:Тимотек, 1998.
- Дорофеев B. JL, Титов И. В., Арзамасцев А. П. Использование метода УФ-спектрофотометрии для количественного определения лекарственных средств группы фторхинолонов. // Вестник ВГУ. Серия: Химия, Биология, Фармация. 2004. — Вып.2. — С. 205−209.
- Каркищенко Н.Н., Хоронько В.В, Сергеева С. А., Каркищенко В. Н. Фармакокинетика. Ростов-на-Дону: Феникс, 2001. — 384 с.
- Коновалов А.А., Дороффев В. Л., Арзамасцев А. П. Фармацевтический анализ лекарственных средств группы фторхинолонов III и IV поколений с использованием метода ВЭЖХ. // Вестник ВГУ. Серия: Химия, Биология, Фармация. 2004. -Вып.2. — С. 216−221.
- Ю.Мирошниченко И. И. Основы фармакокинетики. Москва: ГЭОТАР-МЕД, 2002.-192 с.
- П.Падейская Е. Н. Фторхинолоны: значение, развитие исследований, новые препараты, дискуссионные вопросы. // Антибиотики и химиотерапия. — 1998.-Вып. 11.-С. 38−44.
- Платонов А.Е. Статистический анализ в медицине и биологии: задачи, терминология, логика, компьютерные методы. — Москва: Издательство РАМН, 2000. 52 с.
- Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ / Под общ. ред. Р. У. Хабриева. М.: ОАО Изд-во «Медицина», 2005. — 832 с.
- Н.Соловьев В. Н., Фирсов А. А., Филов В. А. Фармакокинетика. — М.: Медицина, 1980.-423 с.
- Стыскин E. JL, Ициксон Л. Б., Брауде Е. В. Практическая высокоэффективная жидкостная хроматография. Москва: Химия, 1986. -288 с.
- Сюбаева С.Е., Дорофеев В. Л., Арзамасцев А. П. Использование метода ВЭЖХ в анализе лекарственных средств группы фторхинолонов. // Вестник ВГУ. Серия: Химия, Биология, Фармация. 2004. — Вып.2. — С. 258−265.
- Хеншен А., Хупе К.-П., Лотшпайх Ф., Вёльтер В. (ред.) Высокоэффективная жидкостная хроматография в биохимии. Москва: Мир, 1988.-688 с.
- Цой А.Н., Архипов В. В. Спарфлоксацин в терапии инфекционных заболеваний. // Лечащий врач. 2006. — Вып. 8. — С.2−11.
- Шатц В.Д., Сахартова О. В. Высокоэффективная жидкостная хроматография: основы теории, методология. Применение в лекарственной химии. Рига: Зинатне, 1988. — 390 с.
- Шмелев Е.И., В.И. Чуканов. Применение фторхинолонов при туберкулезе. // Пульмонология и фтизиатрия. 2000. — Vol.2(10). — Р. 429 431.
- Ahsan F., Rivas I.P., Khan М.А., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers liposomes and microspheres on the phagocytosis by macrophages. // J. Control Release. 2002 Vol. 79(1−3) P.29−40.
- Ain Q., Sharma S, Khuller GK, Garg SK. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. // J. Antimicrob Chemother.- 2003.- Vol. 51(4) .- P.931−938.
- Ain Q., Sharma S., Garg S.D., Khuller G.D. Role of poly (DL-lactide-co-glycolide) in development of a sustained oral delivery system for antitubercular drug (s). //International Journal of Pharmaceutics.-2002.-Vol.239.-P. 37−46.
- Alyautdin R., Gothier D., Petrov V., et al. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of the polysorbate 80 coated poly (butyl cyanoacrylate) nanoparticles. // Eur J Pharm and Biopharm. — 1995. — Vol. 41(1). — P.44.
- Alyautdin R.N., Petrov V.E., Kreuter J, Langer K., Kharkevich D.A. Delivery of loperamide across the blood-brain barrier with polysorbate 80 coated poly-butylcyanoacrylate nanoparticles. // Pharm Res. 1997. — Vol. 14(3). — P. 325 328.
- Alyautdin R.N., Rrichel A., Lobebberg R., et al. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. // J Drug Target. 2001. — Vol. 9(3). -P. 209−221.
- Alyautdin R.N., Tezikov E.B., Ramga P., et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80 coated polybutylcyanoacrylate nanoparticles: in situ brain perfusion study. // J
- Microencapsul. 1998. — Vol. l5(l). — P. 67.
- Arnold M.M., Gorman E.M., Shieber L.J., Munson EJ., Berklad C. NanoCipro encapsulation in monodispaerse large porous PLGA microparticles. // J Control Release. -2007. Vol.121 (1−2)/ - P.100−109.
- Aso Y., Yoshioka S., Po A.L.W., Terao, Т., Effect of temperature on mechanisms of drug-release and matrix degradation of poly (D, L-lactide) microspheres. // J. Controlled Release.-1994. Vol.31.- P.33−39.
- Azoulay-Dupuis, E., E. Vallee, J. P. Bedos, and J. J. Pocidalo. Efficacy of sparfloxacin (SPFX) in experimental mouse pneumonia models. // Program Abstr. 30thlntersci. Conf. Antimicrob. Agents Chemother., abstr. 1245.
- Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of art. // Crit Rev Ther Drug Carrier Syst. 2004. — Vol. 21. — P.387−422.
- Balland O., Pinto-Alphandary H., Pecquet S., Andremont A., and Couvreur, P. The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. // J. Antimicrob. Chemother.-1994 Vol.33(3).- P.509−522.
- Behan N, Birkinshaw C, Clarke N. Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation // Biomaterials.-2001 Jun.- Vol.22(11).- P.1335 -1344.
- Ben-Dov I., and G. R. Mason. Drug-resistant tuberculosis in a Southern California Hospital. Trends from 1969 to 1984. // Am. Rev. Respir. Dis. 1994.- Vol.35.-P.1307−1310.
- Bodmeier R. and Mcginity, J.W., Solvent selection in the preparation of poly (D, L-Lactide) micro-spheres prepared by the solvent evaporation method. // Int. J. Pharm.-1998.- Vol.43.- P. 179−186.
- Borner K., Borner E., and Lode H. Determination of sparfloxacin in serum and urine by high-performance liquid chromatography. // J. Chromatogr. — 1992, Vol.579(2), P: 285−289.
- Bouissou C., Van der Walle C. Poly (lactic-co-glycolic acid) microspheres. // J. Taylor and Francis Group.: 2006. — P. 81−93.
- Brady J.M., Cutright D.E., Miller R.A., and Barristone G.C., Resorption rate, route of elimination and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. // J. Biomed. Mater. Res.- 2003.- Vol.7.- P.155−166.
- British Pharmacopeia (2009)
- Bummer PM. Physical chemical considerations of lipid-based oral drug delivery: solid lipid nanoparticles. // Crit Rev Ther Drug Carrier System. — 2004.- Vol.21.-P. 1−20.
- Cao S.X., Zhang J.Y., Ji X.M., and Liu H.M. Quantitative analysis of sparfloxacin injection by high performance liquid chromatography. // Se Pu -2001, Vol. l9(5), P: 454−456.
- Chaw C.S., yang Y.Y., Lym I.J., Phan T.T. Water-soluble betamethasone-loaded poly (lactide-co-glycolide) hollow microspheres as a sustained release dosage form. // J. microencapsulation. 2003. — Vol.20(3). — P.349−359.
- Choi S.H., Park T.G. G-CSF loadedbiodegradable PLGA nanoparticles prepared by single oil-in-water emulsion method. //Int J Pharm. 2006. — Vol. 311(1−2). P.223−228.
- Chu D. T. W., and P. B. Fernandes. Structure-activity relationships of the fluoroquinolones. // Antimicrobial Agents Chemotherapy .-1998.- Vol. 33.-P.131−135.
- Conley J, Yang H, Wilson T, и соавт Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularenis infection in mice. // Antimicrobial Agents Chemother.-1997.-Vol.41.-P.1288−1292.
- Culliton B. J. Drug-resistant ТВ may bring epidemic. // Nature (London).- 1998.-Vol. 356.- P:473.
- Damge C., Michel C., Aprahamian M., Couvreur P., and Devissaguet J.P. Nanocapsules as carriers for oral peptide delivery. // J. Controlled Release.-I990.-Vol. 13(2—3).-P.233−239.
- Deng M. and Uhrich K.E. Effects of in vitro degradation on properties of poly (D, L-lactide-co-glycolide) pertinent to its biological performance // J. Mater. Sci.— Mater. Med.-2002.-Vol. 13.-P. 1091−1096.
- Dhillon J, Fielding R, Adler-Moore J, Goodall RL, Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. // J Antimicrob Chemother.- 2001 Dec. Vol.48(6). — P.869−76.
- Donald PR, Sirgel FA, Venter A, Smit E, Parkin DP, Van de Wal BW, Mitchison DA The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosis. // J Antimicrob Chemother. 2001 Dec/ -48(6). — P.877−880
- Drug Information for the Health Care Professional USP DI, 23rd ed., 2003.
- Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. // J Antimicrob Chemother. 2001 Jun. -Vol.47(6). — P.829−835.
- Dutt M, Khuller GK. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. // Int J Antimicrob Agents. 2001 Feb. -Vol.l7(2).-P.l 15−122.
- Dutt M, Khuller GK. Therapeutic efficacy of Poly (DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. // Antimicrob Agents Chemother. 2001 Jan. -Vol.45(l). -P.363−366.
- Elder AC, Gelein R, Oberdorster G, Finkelstein J, Notter R, Wang Z. Efficient depletion of alveolar macrophages using intratracheally inhaled aerosols of liposome-encapsulated clodronate. // Exp Lung Res.- 2004 Mar. Vol.30 (2). -P.105−120.
- Ellard, G. A. Absorption, metabolism and excretion of pyrazinamide in man.// Tubercle. 1969.-Vol.50. -P.:144−158.
- European Pharmacopeia, 6th ed. (2007).
- Fattal E., Youssef M., Couvreur P., and Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. // Antimicrob. Agents Chemother.- 1999.- Vol.33(9). P. 1540−1543.
- Fawaz F., Bonini F., Maugein J., Lagueny A.M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. // International Journal of Pharmaceutics. 1998. Vol.168.-P. 255−259
- Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. // J Drug Target.- 2004. Vol.12. — P.:65−70.
- Fuminori I., Hiroyuki F., Kimiko M. Factor affecting the loading efficiency of water-soluble drugs in PLGA microspheres. // Colloids and Surfaces В.- 2008.1. Vol 61. -P.25−29.
- Fuminori I., Hiyuki F., Kimiko M. Incorporation of water-soluble drugs in PLGA microspheres. // Colloids and Surfaces B. 2007. — Vol.54. — P. 173 178.
- Gaspar MM, Neves S, Portaels F, Pedrosa J, Silva MT, Cruz ME. Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. // Antimicrob Agents Chemother. 2000 Sep. — Vol.44(9). — P.2424−2430.
- Gelperina S., Kisich K., Iserman M., and Heilfets. The potential adventages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. // American journal of respiratory and critical care medicine. 2005. — Vol. 172.1. P.1487−1490.
- Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Torchilin V., and Langer, R., Biodegradable long-circulating polymeric nanospheres. // Scienc. — 1994.-Vol. 263(5153).-P. 1600−1603.
- Grislain L., Couvreur P., Lenaerts V., Roland, M., Deprez-Decampeneere, D., and Speiser, P. Pharmacokinetics and distribution of a biodegradable drug-carrier. // Int. J. Pharm.-1993. Vol. 15(3). — P. 335−345.
- Grosset, J. H. Present status of chemotherapy for tuberculosis. // Rev. Infect. Dis.1989. Vol.11. — P.347−352.
- Jeong YI, Na HS, Seo DH, Kim DG, Lee HC Jang MK, Nang Sk, Roh SH, Kim SI, and Nah JW. Ciprofloxacin-encapsulated poly (dl lactde-co-glycolide) nanoparticles and its antibacterial activity. // Int J Pharm. 2008
- Mar.-Vol. 352 (1−2). -P.317−323.
- Ji. В., С. Truffot-Pernot, and J. Grosset. In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. // Tubercle. 1991. -Vol. 72. —P.181−186.
- Kabanov A.V., Lemieux P., Vinogradov S., Alakhov V. Pluronic® block copolymers: novel functional molecules for gene therapy. // Advanced Drug Delivery Reviews. 2004. — Vol. 54. — P. 223−233
- Kamberi M., Kamberi P., Hajime N., Uemura N., Nakamura K., and Nakano S. Determination of sparfloxacin in plasma and urine by a simple and rapid liquid chromatographic method. // Ther. Drug Monit. 1999, Vol.21(4), P:411−415.
- Khuller G.K., and Pandey R. Sustained Release drug delivery systems in management of tuberculosis. // Indian J Chest Dis Allied Sci. 2003. — Vol.45. — P. 229−230.
- Khuller G.K., Kapur M., Sharma S. Liposome technology for for drug delivery against mycobacterial infections. // Curr Pharm Des. 2004. — Vol.10. — 32 633 274.
- Klose D., Siepmann F., Elkharraz K., Krenzlin S., Siepmann J. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. '// International Journal of Pharmaceutics. 2006. — Vol.314. — P. 198−206.
- Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). // Brain Res. 1995. — Vol. 674. — P. 171−174.
- Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R: Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. // J Drug Target. 2002. — Vol. 10. — P. 317
- Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. // Int J Antimicrob Agents.- 2002 Oct. — Vol.20(4). -P.301−304.
- Lamprecht A. Ubrich N., Hombreiro M., Lehr C., Hoffman M., Maincent P. Biodegradable monodispersed nanopartcles prepared by pressure homogenization-emulsifiction. // International Journal of Pharmaceutics. — 1999.-Vol.184.-P.97−105.
- Lemaire V., Belair J., and Hildgen P. Structural modeling of drug release from biodegradable porous matrices based on a combined diffusion/erosion process. // Int. J. Pharm.- 2003. Vol.258. — P. 95−107.
- Luna-Herrera J., Duzgune? N., Flasher D., Reddy M.,, and Gangadharam P. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin.// Antimicrob Agents Chemother. 1996. — Vol.40(l 1). — P.2618−2621.
- Lyon D.J., Cheung S.W., Chan C.Y., and Cheng A.F.B. Rapid HPLC assay of clinafloxacin, fleroxacin, levofloxacin, sparfloxacin and tosufloxacin. // J. Antimicrob. Chemother. 1994, Vol.34, P:446−448.
- Manisha Dutt and G.L. Kuller. Chemotherapy of Mycobacterium tuberculosis infection in mice with a combination of isoniazid and rifampicin entrapped in
- Poly (dl-lactide-co-glycolide) microparticles. // J. Antimicrobial Chemotherapy.-2001. Vol.47. — P: 829−835.
- Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. // Pharmacol Rev 2001. Vol.53. — P. 283 318
- Montay G., Bruno R., Vergniol J.C., и соав. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. // J. Clin. Pharmacol. 1994, Vol.34, P: 1071−1076.
- Muller, R.H. Colloidal Carriers for Controlled Drug Delivery and Targeting. // CRC Press, Boca Raton FL. 1991. — P. 7−10.
- Pandey R, Khuller G.R. Solid lipid particle-based inhalable suistained drug delivery system against experimetal tuberculosis. // Tuberculois (Edinb). -2005. Vol.85. — P.227−234.
- Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. // Tuberculosis (Edinb). 2003. — Vol.83(6). — P.373−378.
- Pistner H., Bendix D.R., Muhling J., and Reuther, J.F. Poly (L-lactide) — a long-term degradation study invivo. Analytical characterization. // Biomaterials. 1993. — Vol. 14. — P.291−298.
- Pretet S., A. Lebeaut R. Parrot C. Truffot J. Grosset A. T. Dinh-Xuan, and G.E.T.I.M. Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. // Eur. Respir. J.-1999. Vol. 5:680 684.
- Quenelle DC, Staas JK, Winchester GA, Barrow EL, Barrow WW. Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. // Antimicrob Agents Chemother.- 1999 May. Vol.43(5). — P. 1144−1151.
- Salem I.I., Flasher D.L., Duzgunes N. Liposome-encapsulated antibiotics. И Methods Enzymol. 2005. — Vol.391. -P.261−291.
- Seijo В., Fattal E., Roblot-Treupel L., Couvreur P. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. // International Journal of Pharmaceutics. 1999. — Vol.62. — P. 1−7
- Sethuraman VV, Hickey AJ. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. // AAPS PharmSciTech. -2002. — Vol.3(4). — P.28.
- Sham J.O., Zhang Y., Filay W.H., Lobenberg R. Formulation and cheracterization of spray-dry powders containing nanoparticles for aerosol delivery to the lung. // Int J Pharm. 2004. — Vol.269. — P.457−467.
- Shamenkov D A- Petrov V E- Alyautdin R N. Effects of apolipoproteins on dalargin transport across the blood-brain barrier. // Bulletin of experimental biology and medicine. 2006. — Vol. — 142(6). — P.703−6.
- Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) encapsulated antitubercular drugs at subtherapeutic dose against experimental tuberculosis. // Int J Antimicrob Agents. 2004. — Vol.24. — P.599−604.
- Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. // J Antimicrob Chemother. 2004. — Vol.54. -P.761−766.
- Simardeep G., Lobenberg R, Thbitha K., Shirzad A., Wilson R., and Elmar J. Nanoparticles: Characteristics, mechanisms of action, and toxicity in pulmonary drug delivery — a Review. // Journal of biomesical nanotechnology.- 2007. Vol.3. — P. 107−119.
- Spenlehauer G., Vert M., Benoit J.P., and Boddaert A., Invitro and invivo degradation of poly (D, L-lactide glycolide) type microspheres made by solvent evaporation method. // Biomaterials. 2006. — Vol. 10, 557−563.
- Suarez S, O’Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. // J Antimicrob Chemother. 2001 Sep. — Vol.48(3). -P.431−434.
- Thanoo B.C., Doll W.J., Mehta R.C., Digenis G.A., and DeLuca P.P., Biodegradable indium-Ill labeled microspheres for in vivo evaluation of distribution and elimination, Pharm. Res. 1995. — Vol.12. — P. 2060−2064.
- The United States pharmacopeia, 30th revision (2007).
- Trautmann M., Ruhnke M., borner K., Wagner J., and Koeppe P. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. // Antimicrobial Agens and chemotherapy. 1996. — Vol. 40(3). -P. 776−779.
- Tsapis N., Bennett D., Jackson В., Weitz D.A., Edwards D.A. Trojan particles: large porous carrier of nanoparticles for drug delivery. // Proc Natl Acad Sci USA. 2002. — Vol.99. — P.12 001−12 005.
- Uchegbu I. Polymers in Drug Delivery. CRC Taylor & Francis Group, 2006.- P. 70−78.
- Valerie L., Chantal T.P., Anne P., Jacques G., and Baohong J. Powerful Bactericidal Activity of Sparfloxacin (AT-4140) against Mycobacterium tuberculosis in Mice. // Antimicrobial agents and chemotherapy. 1993. — Vol. 37(3). — P.407−413.
- Verdun C., Brasseur F., Vranckx H., Couvreur P., and Roland M., Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. // Cancer Chemother. Pharmacol.- 1990. Vol.26(l). -P. 13−18.
- Vinogradov S.V., Bronich Т.К., Kabanov Alexander V. Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. // Advanced Drug Delivery Reviews. 2002. -Vol. 54. — P. 135−147
- Von Burkersroda F., Schedl L., and Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. // Biomaterials. 2002. -Vol. 23. — P. 4221^4231.
- Williams A., Graham J.H., Simon O., Karen E.G. Evaluation of vaccines in the EU ТВ Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. // Tuberculosis. 2005. — Vol.85. — P.29−38.
- Wissing S.A., Kayser O., Muller R.H. Solid lipid nanoparticles for parenteral drug delivery. // Adv Drug Deliv Rev. 2004. — Vol.56. — P. 1257−1272.
- World Health Organization Working Group. 1991. Tuberculosis research and development. WHO/TB/91−162. World Health Organization, Geneva.
- Yoshioka S., Aso Y., and Kojima S., Drug release from poly (dl-lactide) microspheres controlled by gamma-irradiation. // J. Controlled Release. — 1995. -Vol. 37.-P. 263−267.
- Zhu G., Mallery S.R., and Schwendeman S.P., Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). // Nat. Biotechnol.-2000.-Vol.18.-P. 52−57.